S 2689: Congress to the rescue on stem cells? (Not)
In my last post on stem cells, I painted a pretty bleak picture. Based on warning letters and recent FDA guidance documents, the clinical use of autologous stem cell therapeutics is essentially over. The only way patients are going to be able to receive autologous stem cell transplants for non-homologous use is either in FDA approved clinical trials or outside the United States. This hasn’t gone unnoticed in Congress. In March, 2016, a bill was introduced, by Senator Mark Kirk…